[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.21.0″ _module_preset=”default” background_color=”gcid-3cfc8c0c-5557-4a5d-9dab-24e78d615311″ custom_padding=”61px|||||” collapsed=”on” global_colors_info=”{%22gcid-3cfc8c0c-5557-4a5d-9dab-24e78d615311%22:%91%22background_color%22%93}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.24.3″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” custom_margin=”-47px|||||” custom_padding=”2px||0px|||” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]<\/p>\n
This is licensing only<\/strong> and does not include any costs for regulatory and clinical trial work. Initial license fee is $50,000 upfront plus a $10,000 minimum annual royalty for a total of $60,000. Phase 1 is an additional $100,000, Phase 2 is $250,000, Phase 3 $500,000, and BLA is $1,000,000. Each year an annual royalty payment of $10,000 will be due on the anniversay date of initial licensing. And finally there is a 6% royalty due on gross revenues from any succesful applications for use in the general population. This royalty will continue through the life of the patent(s) covering any particular disease.<\/p>\n To enter into clinical trials you may be required to conduct preclinical experiments before you author and file Investigational New Drug Applications (IND). We are available for consulting and assistance in authoring IND\u2019s.<\/p>\n <\/p>\n https:\/\/patents.justia.com\/patent\/20220267730<\/a><\/span><\/p>\n <\/p>\n<\/div>\n<\/div>\n https:\/\/patents.justia.com\/patent\/20220306994<\/a><\/span><\/p>\n <\/p>\n<\/div>\n<\/div>\n https:\/\/patents.justia.com\/patent\/20220235325<\/a><\/span><\/p>\n <\/p>\n<\/div>\n<\/div>\n https:\/\/patents.justia.com\/patent\/20220403330<\/a><\/span><\/p>\n <\/p>\n<\/div>\n<\/div>\nThe following list of StemVacs\u2122<\/strong> cancer immunotherapy patents are available for licensing.<\/strong><\/h4>\n
EX VIVO GENERATION OF IMMUNOCYTES RECOGNIZING BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) EXPRESSING CANCER STEM CELLS<\/div>\n
CHIMERIC CELLS COMPRISING DENDRITIC CELLS AND ENDOTHELIAL CELLS RESEMBLING TUMOR ENDOTHELIUM<\/div>\n
STIMULATION OF DENDRITIC CELL ACTIVITY BY HOMOTAURINE AND ANALOGUES THEREOF<\/div>\n
COMPOSITIONS CAPABLE OF STIMULATING IMMUNITY TOWARDS TUMOR BLOOD VESSELS<\/div>\n
AUGMENTATION OF NATURAL KILLER CELL ACTIVITY AND INDUCTION OF CYTOTOXIC IMMUNITY USING LEUKOCYTE LYSATE ACTIVATED ALLOGENEIC DENDRITIC CELLS: STEMVACS<\/div>\n